Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hainan Gourd Doll Pharmaceutical Group is a leading Chinese pharmaceutical company specializing in the research, development, and manufacturing of pediatric medicines. The company is widely recognized for its Huluwa brand, which focuses on Traditional Chinese Medicine (TCM) and chemical drug formulations specifically designed for children's health. Its extensive product portfolio covers major therapeutic areas such as respiratory, digestive, and anti-infective treatments, with its flagship Pediatric Lung Heat Coughing and Asthma Granules holding a significant market share in China. Listed on the Shanghai Stock Exchange, Gourd Doll Pharmaceutical operates multiple GMP-certified production bases and is committed to advancing the standardization and safety of pediatric pharmacotherapy.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Hainan Gourd Doll Pharmaceutical.